AnimalGAN: A Generative Adversarial Network Model Alternative to Animal Studies for Clinical Pathology Assessment
Xi CheniD, Ruth Angela RobertsiD, Zhichao LiuiD, Weida TongiD
Abstract
Animal studies are unavoidable in evaluating chemical and drug safety. Generative Adversarial Networks (GANs) can generate synthetic animal data by learning from the legacy animal study results, thus serving as an alternative approach to assess untested chemicals. AnimalGAN, a GAN method to simulate 38 rat clinical pathology measures, was developed with significant robustness even for the drugs that vary significantly from these used during training, both in terms of chemical structure, drug class, and the year of FDA approval. AnimalGAN showed a comparable performance in hepatotoxicity assessment as animal studies and outperformed the optimal prediction of 12 traditional regression approaches for almost all clinical pathology measures. Using AnimalGAN, a virtual experiment of 100,000 rats ranked hepatotoxicity of three similar drugs that correlated with the findings in human population. AnimalGAN represented a significant step with artificial intelligence towards the global effort in replacement, reduction, and refinement (3Rs) of animal use.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 65
- FWCI
- 9.27
- Field percentile
- top 1%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Deep Learning-based Modeling for Preclinical Drug Safety Assessment
Guillaume Jaume, Simone de Brot, … Faisal Mahmood·bioRxiv·Jul 20, 2024
- Leveraging High-Throughput Screening Data and Conditional Generative Adversarial Networks to Advance Predictive Toxicology
Adrian J. Green, Martin J. Mohlenkamp, … David M. Reif·bioRxiv·Oct 2, 2020
- Large-scale experimental validation of phenotype-guided generative AI for de novo drug discovery
Jure Fabjan, Joanna M. Wenda, … David Rouquié·bioRxiv·Sep 13, 2025
- Bridging Organ Transcriptomics for Advancing Multiple Organ Toxicity Assessment with a Generative AI Approach
Ting Li, Xi Chen, Weida Tong·npj Digital MedicinePeer-reviewed·Nov 5, 2024
- AI-driven Discovery of Morphomolecular Signatures in Toxicology
Guillaume Jaume, Thomas Peeters, … Faisal Mahmood·bioRxiv·Jul 19, 2024
- Improving drug safety predictions by reducing poor analytical practices
S. E. Lazic, D. Williams·bioRxiv·Sep 25, 2020